<https://www.empr.com/home/news/drugs-in-the-pipeline/fda-wants-more-info-before-approving-exparel-for-post-op-nerve-block/>
<http://schema.org/description>
"The FDA has issued a Complete Response Letter (CRL) for the supplemental New Drug Application (sNDA) for the use of Exparel (bupivacaine liposome injectable suspension) in nerve block to provide postsurgical analgesia."
<https://www.empr.com/home/news/drugs-in-the-pipeline/fda-wants-more-info-before-approving-exparel-for-post-op-nerve-block/>